Shaping the space of a residential complex for seniors on the basis of own research

Przedmiotem artykułu jest próba odpowiedzi na pytanie: jak należycie kształtować środowisko życia i zamieszkania przeznaczone dla osób starszych? Głównym celem opracowania jest stworzenie wytycznych projektowych związanych z kształtowaniem przestrzeni kompleksu mieszkaniowego dedykowanego seniorom przy jednoczesnym uwzględnieniu wpływu architektury oraz środowiska na użytkowników obiektu. Wszystkie wskazówki oraz dane prowadzące do budowy programu funkcjonalno-powierzchniowego kompleksu powstały na bazie wykonanych badań i analiz przedprojektowych. Efektem końcowym, będącym odpowiedzią na postawione we wstępie pytanie, był projekt koncepcyjny założenia architektonicznego. W skład kompleksu wchodzi obiekt domu seniora oraz samodzielne mieszkania położone w dwukondygnacyjnych budynkach. Całość założenia została wzbogacona zewnętrznymi przestrzeniami zielonymi oraz ogrodami sensorycznymi.The subject of this paper is an attempt to answer the question - how to properly shape the living and residential environment intended for the elderly? The main objective of the study is to create design guidelines related to the shaping of the space of a residential complex dedicated to seniors, while taking into account the impact of architecture and the environment on the users of the facility. All the guidelines and data leading to the construction of the functional and spatial programme of the complex were created on the basis of pre-design studies and analyses. The final result, being an answer to the question posed in the introduction, was a conceptual design of the architectural set. The complex consists of a Senior Citizen Home and separate flats located in two-storey buildings. The entire complex is enriched with outdoor green spaces and sensory gardens

Determinants of health as predictors for differential antibody responses following SARS-CoV-2 primary and booster vaccination in an at-risk, longitudinal cohort

Post vaccine immunity following COVID-19 mRNA vaccination may be driven by extrinsic, or controllable and intrinsic, or inherent health factors. Thus, we investigated the effects of extrinsic and intrinsic on the peak antibody response following COVID-19 primary vaccination and on the trajectory of peak antibody magnitude and durability over time. Participants in a longitudinal cohort attended visits every 3 months for up to 2 years following enrollment. At baseline, participants provided information on their demographics, recreational behaviors, and comorbid health conditions which guided our model selection process. Blood samples were collected for serum processing and spike antibody testing at each visit. Cross-sectional and longitudinal models (linear-mixed effects models) were generated to assess the relationship between selected intrinsic and extrinsic health factors on peak antibody following vaccination and to determine the influence of these predictors on antibody over time. Following cross-sectional analysis, we observed higher peak antibody titers after primary vaccination in females, those who reported recreational drug use, younger age, and prior COVID-19 history. Following booster vaccination, females and Hispanics had higher peak titers after the 3 rd and 4 th doses, respectively. Longitudinal models demonstrated that Moderna mRNA-1273 recipients, females, and those previously vaccinated had increased peak titers over time. Moreover, drug users and half-dose Moderna mRNA-1273 recipients had higher peak antibody titers over time following the first booster, while no predictive factors significantly affected post-second booster antibody responses. Overall, both intrinsic and extrinsic health factors play a significant role in shaping humoral immunogenicity after initial vaccination and the first booster. The absence of predictive factors for second booster immunogenicity suggests a more robust and consistent immune response after the second booster vaccine administration

Examining the effect of SARS-CoV-2 pandemic-induced stress and anxiety on humoral immunity in healthcare workers

OBJECTIVEThe effect of stress on vaccine-induced humoral immunity and therapeutic interventions to mitigate pandemic-related stress remain under-explored.METHODSParticipants in a longitudinal cohort study (n = 189) completed a validated measure, 7-instrument Generalized Anxiety Disorder (GAD-7), and 10-instrument stress measure (SM-10) to assess stress and anxiety following SARS-CoV-2 vaccination. Serum was collected to obtain SARS-CoV-2 antibody titer levels.RESULTSParticipants experienced increased stress due to the SARS-CoV-2 pandemic with a positive correlation between GAD-7 scores and peak antibody (Ab) titers overall; however, there was a negative association with scores commensurate with severe anxiety. Healthcare workers (HCW) and younger participants were more significantly affected by anxiety.CONCLUSIONSMild anxiety levels may have immune-enhancing effects, whereas severe anxiety may cause antibody generation reduction. Mental health-focused interventions are imperative for younger adults and HCWs. Young adults may be more resilient to increased stress levels

Post-primary vaccination mean Log₂ Ab across COVID vaccine groups.

There was no significant difference (T = 1.26, p = 0.211) between mean log2 Ab between participants who received Moderna mRNA-1273 (13.50 ± 1.71) or Pfizer BNT162b2 vaccines (13.14 ± 1.64) for their primary vaccination after 2 weeks of vaccination onset.</p

Predictors for reactogenicity and humoral immunity to SARS-CoV-2 following infection and mRNA vaccination: A regularized, mixed-effects modelling approach

The influence of pre-existing humoral immunity, inter-individual demographic factors, and vaccine-associated reactogenicity on immunogenicity following COVID vaccination remains poorly understood. Ten-fold cross-validated least absolute shrinkage and selection operator (LASSO) and linear mixed effects models were used to evaluate symptoms experienced by COVID+ participants during natural infection and following SARS-CoV-2 mRNA vaccination along with demographics as predictors for antibody (AB) responses to recombinant spike protein in a longitudinal cohort study. In previously infected individuals (n=33), AB were more durable and robust following primary vaccination when compared to natural infection alone. Higher AB were associated with experiencing dyspnea during natural infection, as was the total number of symptoms reported during the COVID-19 disease course. Both local and systemic symptoms following 1 and 2 dose (n=49 and 48, respectively) of SARS-CoV-2 mRNA vaccines were predictive of higher AB after vaccination. Lastly, there was a significant temporal relationship between AB and days since infection or vaccination, suggesting that vaccination in COVID+ individuals is associated with a more robust immune response. Experiencing systemic and local symptoms post-vaccine was suggestive of higher AB, which may confer greater protection

Linear mixed effects model (LMM) evaluating the relationship between post-primary vaccination antibody titers and time, COVID-19 vaccine manufacturer, prior COVID-19 infection status, and biological sex.

Linear mixed effects model (LMM) evaluating the relationship between post-primary vaccination antibody titers and time, COVID-19 vaccine manufacturer, prior COVID-19 infection status, and biological sex.</p

Other measured extrinsic and intrinsic health factors among the primary vaccination sub-cohort.

Other measured extrinsic and intrinsic health factors among the primary vaccination sub-cohort.</p

Cohort extrinsic health factor summary table.

Post vaccine immunity following COVID-19 mRNA vaccination may be driven by extrinsic, or controllable and intrinsic, or inherent health factors. Thus, we investigated the effects of extrinsic and intrinsic on the peak antibody response following COVID-19 primary vaccination and on the trajectory of peak antibody magnitude and durability over time. Participants in a longitudinal cohort attended visits every 3 months for up to 2 years following enrollment. At baseline, participants provided information on their demographics, recreational behaviors, and comorbid health conditions which guided our model selection process. Blood samples were collected for serum processing and spike antibody testing at each visit. Cross-sectional and longitudinal models (linear-mixed effects models) were generated to assess the relationship between selected intrinsic and extrinsic health factors on peak antibody following vaccination and to determine the influence of these predictors on antibody over time. Following cross-sectional analysis, we observed higher peak antibody titers after primary vaccination in females, those who reported recreational drug use, younger age, and prior COVID-19 history. Following booster vaccination, females and Hispanics had higher peak titers after the 3rd and 4th doses, respectively. Longitudinal models demonstrated that Moderna mRNA-1273 recipients, females, and those previously vaccinated had increased peak titers over time. Moreover, drug users and half-dose Moderna mRNA-1273 recipients had higher peak antibody titers over time following the first booster, while no predictive factors significantly affected post-second booster antibody responses. Overall, both intrinsic and extrinsic health factors play a significant role in shaping humoral immunogenicity after initial vaccination and the first booster. The absence of predictive factors for second booster immunogenicity suggests a more robust and consistent immune response after the second booster vaccine administration.</div

Linear mixed effects model (LMM) evaluating the relationship between BV1 antibody titers and time, COVID-19 vaccine manufacturer, prior COVID-19 infection status, and biological sex.

Linear mixed effects model (LMM) evaluating the relationship between BV1 antibody titers and time, COVID-19 vaccine manufacturer, prior COVID-19 infection status, and biological sex.</p